Biotech startups in Jiangsu, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Weikaier Pharmaceutical Technology | Nanjing | Series C | $29.6M | 2026-06-02 |
| D3 Bio | Wuxi Shi | Series B | $108.0M | 2025-12-09 |
| HemaCell | Suzhou | Series B | $14.8M | 2026-06-02 |
| iCamumo | Suzhou | Series A | $14.4M | 2026-03-09 |
| Yuce Biotechnology | Suzhou | Series B | $7.4M | 2026-08-31 |
| IMPACT Therapeutics | Nanjing | Series D | $34.6M | 2024-11-15 |
| CureGenetics | Suzhou | Series B | $9.0M | 2024-03-28 |
| PRCXI Biotechnology | Suzhou | Series A | $14.0M | 2025-12-31 |
8 rows of the CSV in 5 of its 18 columns.
- The 225 biotech startups in Jiangsu, China have raised $4.0B in total.
- 47 of them closed their most recent round in the last 12 months, $661.5M combined.
- The largest of those rounds is D3 Bio's $108.0M Series B, dated December 2025.
- The most recent is Enorna's $15.0M seed round on 29 October 2026.
- Qiming Venture Partners is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 195 companies (87%).
- 34% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (34% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
15 of 225| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| iCamumo | iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. | Biotech | Suzhou | Series A | $14.4M | 2026-03-09 | $75.2M | Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment | 51 to 100 | 2021 |
| Micro-Ray Technology | Micro-Ray Technology supplies X-ray tubes and component solutions for medical imaging equipment such as CT machines. | Biotech | Suzhou | Seed | $14.4M | 2026-01-23 | $14.4M | Suzhou Xiangcheng Financial Holding Group | 11 to 50 | 2021 |
| PRCXI Biotechnology | PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. | Biotech | Suzhou | Series A | $14.0M | 2025-12-31 | $55.0M | Qiming Venture Partners, SAIF Partners | 101 to 250 | 2014 |
| D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| Kunshi Biotechnology | Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. | Biotech | Suzhou | Series A | $7.0M | 2025-11-20 | $7.0M | Deshi Capital | 51 to 100 | 2021 |
| IMPACT Therapeutics | IMPACT Therapeutics develops similar drugs to treat cancer. | Biotech | Nanjing | Series D | $34.6M | 2024-11-15 | BioVenture, Lilly Asia Ventures, Decheng Capital +2 | 51 to 100 | 2009 | |
| Wimi bio | Wimi Bio researches and develops gene editing and biological breeding technologies as a high-tech enterprise. | Biotech | Nanjing | Series A | $14.1M | 2024-09-19 | HosenCare Brothers | 51 to 100 | 2017 | |
| Yidao Biotechnology | Yidao Biotechnology researches and develops vaccines and biomedical products. | Biotech | Suzhou | Series D | $25.2M | 2024-05-09 | Qiming Venture Partners, Northern Light Venture Capital | 2017 | ||
| CureGenetics | CureGenetics develops medicines and molecular diagnostics for cancers and genetic diseases. | Biotech | Suzhou | Series B | $9.0M | 2024-03-28 | Qiming Venture Partners, Oriza Holdings, Qingsong Fund +1 | 51 to 100 | 2016 | |
| Atom Bioscience & Pharmaceutical | Atom Bioscience is a clinical-stage biotechnology company. | Biotech | Suzhou | Series D | $82.1M | 2023-10-16 | Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 | 11 to 50 | 2012 | |
| Zenshine Pharma | Zenshine Pharma develops small molecule drugs for cancer and autoimmune diseases. | Biotech | Nanjing | Series C | $13.7M | 2023-10-13 | $28.7M | Matrix Partners China, Cybernaut Venture Capital, Kunlun Capital +2 | 11 to 50 | 2018 |
| Onechip Bioelectronics | Onechip Bioelectronics develops biosensor chips and nanomaterials. | Biotech | Zhangjiagang | Series B | $13.7M | 2023-09-28 | Matrix Partners China, Qiming Venture Partners, Xiamen C&D Emerging Industry Equity Investment +1 | 11 to 50 | 2014 |
Table 1. Biotech startups in Jiangsu, China: the 15 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 225.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Nanjing | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| 3 | HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| 4 | iCamumo | iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. | Biotech | Suzhou | Series A | $14.4M | 2026-03-09 | $75.2M | Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment | 51 to 100 | 2021 |
| 5 | Micro-Ray Technology | Micro-Ray Technology supplies X-ray tubes and component solutions for medical imaging equipment such as CT machines. | Biotech | Suzhou | Seed | $14.4M | 2026-01-23 | $14.4M | Suzhou Xiangcheng Financial Holding Group | 11 to 50 | 2021 |
| 6 | PRCXI Biotechnology | PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. | Biotech | Suzhou | Series A | $14.0M | 2025-12-31 | $55.0M | Qiming Venture Partners, SAIF Partners | 101 to 250 | 2014 |
| 7 | Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| 8 | Kunshi Biotechnology | Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. | Biotech | Suzhou | Series A | $7.0M | 2025-11-20 | $7.0M | Deshi Capital | 51 to 100 | 2021 |
Table 2. Biotech startups in Jiangsu, China: the 8 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 4 | 2% | 1 | PRCXI Biotechnology |
| 2 | Matrix Partners China | Venture capital firm | Beijing, China | 3 | 1% | 1 | D3 Bio |
| 3 | Oriza Holdings | Venture capital firm | Suzhou, China | 3 | 1% | ||
| 4 | China Life Private Equity Investment | Private equity firm | Beijing, China | 2 | 1% | 1 | Weikaier Pharmaceutical Technology |
| 5 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 2 | 1% | 1 | HemaCell |
| 6 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 2 | 1% | 1 | HemaCell |
| 7 | Delian Capital | Venture capital firm | Beijing, China | 2 | 1% | 1 | iCamumo |
| 8 | Zhengxuan Investment | Venture capital firm | Shenzhen, China | 2 | 1% | 1 | Yuce Biotechnology |
| 9 | BioVenture | Venture capital firm | Suzhou, China | 2 | 1% | ||
| 10 | EFung Capital | Private equity firm | Shenzhen, China | 2 | 1% | ||
| 11 | Kaitai Capital | Venture capital firm | Hangzhou, China | 2 | 1% | ||
| 12 | SDIC Venture Capital | Venture capital firm | Xicheng, China | 1 | 0% | 1 | Weikaier Pharmaceutical Technology |
| 13 | Nanjing Innovation Capital Group | Venture capital firm | Nanjing, China | 1 | 0% | 1 | Weikaier Pharmaceutical Technology |
| 14 | Dyee Capital | Private equity firm | Xiamen, China | 1 | 0% | 1 | Weikaier Pharmaceutical Technology |
| 15 | Boyu Capital | Private equity firm | Beijing, China | 1 | 0% | 1 | D3 Bio |
Table 3. Biotech startups in Jiangsu, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 195 | 87% | $3.7B |
| Hardware | 4 | 2% | |
| Software | 3 | 1% | $100.0M |
| Artificial intelligence | 2 | 1% |
Table 4. Biotech startups in Jiangsu, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Jiangsu, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups in Jiangsu, China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 5 | 11% | $30.0M |
| September 2026 | 1 | 2% | |
| August 2026 | 4 | 9% | $81.9M |
| July 2026 | 2 | 4% | $29.5M |
| June 2026 | 2 | 4% | $44.3M |
| May 2026 | 6 | 13% | $119.4M |
| April 2026 | 1 | 2% | $29.3M |
| March 2026 | 4 | 9% | $14.4M |
| February 2026 | 2 | 4% | $50.6M |
| January 2026 | 9 | 19% | $65.5M |
| December 2025 | 7 | 15% | $175.3M |
| November 2025 | 4 | 9% | $21.1M |
Table 7. Biotech startups in Jiangsu, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 36 | 16% | $465.1M |
| 2025 | 36 | 16% | $365.8M |
| 2024 | 33 | 15% | $280.0M |
| 2023 | 38 | 17% | $474.4M |
| 2022 | 25 | 11% | $594.5M |
| 2021 | 17 | 8% | $1.0B |
Table 8. Biotech startups in Jiangsu, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 17 | 8% |
| 2020 to 2022 | 58 | 26% |
| 2015 to 2019 | 85 | 39% |
| 2010 to 2014 | 43 | 20% |
| Before 2010 | 17 | 8% |
Table 9. Biotech startups in Jiangsu, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 14 | 8% |
| 11 to 50 | 61 | 34% |
| 51 to 100 | 45 | 25% |
| 101 to 250 | 27 | 15% |
| 251 to 500 | 14 | 8% |
| 501 to 1,000 | 11 | 6% |
| 1,001 to 5,000 | 5 | 3% |
Table 10. Biotech startups in Jiangsu, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Jiangsu, China. On 16 November 2026 that is 225 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 15 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 225 rows: 97 have no round amount, 0 no city and 83 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Jiangsu, China are on the list?
- 225, in the file dated 16 November 2026. 47 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 225 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.